Shareholder Return Policy
The Company's basic policy is to continue paying stable dividends while comprehensively considering factors such
as securing funds to prepare for long-term business development. Furthermore, the Company uses its retained
earnings for R&D investments, production equipment investments, and other measures to strengthen its corporate
structure for sustainable future growth. On the other hand, the Company recognizes that providing fair profit returns
in line with earnings is also an important management priority.
Up to FY2025, based on the “ASKA Pharmaceutical Holdings Takes Action to Implement Management That is Conscious of Cost of Capital and Share Price” announced in November 2023, the Company targeted a consolidated payout ratio of 30%, with a minimum annual dividend per share of 30 yen.
From FY2026 onward, the Company targets a total payout ratio of 40% and has adopted a progressive dividend policy (excluding special dividends).
Dividends in the Current and the Following Period
(As of May 11, 2026)
Based on the above policy and recent earnings trends, the Company plans to set the year-end dividend for the current fiscal year at 33 yen per share. Together with the interim dividend of 27 yen per share already paid, this will result in an annual dividend of 60 yen per share.
In addition, based on the above policy, the Company plans to target a total payout ratio of 40% from the fiscal year ending March 31, 2027 onward. Taking into account the introduction of a progressive dividend policy (excluding special dividends), the Company plans to pay an annual dividend of 65 yen per share for the fiscal year ending March 2027, consisting of an interim dividend of 32 yen per share and a year-end dividend of 33 yen per share.